Mesoblast Limited(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-26 06:19 EST	News	Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript	N/A
2023-05-26 06:19 EST	News	Mesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18M	N/A
2023-05-04 20:51 EST	News	Mesoblast Has A Strong Upside Potential	N/A
2023-03-08 20:50 EST	News	Mesoblast stock surges ~10% on getting FDA review of graft versus host disease therapy	N/A
2023-03-02 11:37 EST	News	Mesoblast Limited. (MESO) Q2 2023 Earnings Call Transcript	N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney disease read more...s, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

See Advanced Chart

General

Name Mesoblast Limited
Symbol MESO
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 102
Fiscal Year EndJune
IPO Date2015-11-13
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.mesoblast.com

Valuation

Forward PE 454.55
Price/Sales (Trailing 12 Mt.) 62.46
Price/Book (Most Recent Quarter) 2.28
Enterprise Value Revenue 70.47

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$0.29
Next Year EPS Estimate $0.17
Operating Margin -682%
Return on Assets -10%
Return on Equity -19%
Revenue 16.45 million
Earnings Per Share -$0.91
Revenue Per Share $0.15
Gross Profit 6.85 million
Quarterly Earnings Growth 1.6%

Highlights

Market Capitalization 1.26 billion
EBITDA -78815000
Analyst Target Price $13.7
Book Value Per Share $4.42

Share Statistics

Shares Outstanding 129.62 million
Shares Float 101.69 million
% Held by Insiders <1%
% Held by Institutions 2.87%
Shares Short 1.88 million
Shares Short Prior Month 2.82 million
Short Ratio 4.29
Short % of Shares Outstanding 2%

Technicals

Beta 2.71
52 Week High $21.28
52 Week Low $3.12
50 Day Moving Average 9.64
200 Day Moving Average 12.23

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Mesoblast Limited (MESO) Dividend Calendar:

Show entries

Search:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount
No data available in table

Showing 0 to 0 of 0 entries

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Show entries

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-02-26	$N/A	-$0.22	-$0.15	-43.61%
2020-09-30	2020-11-19	$N/A	-$0.21	-$0.26	19.04%
2020-06-30	2020-08-26	$N/A	-$0.30	-$0.21	-42.52%
2020-03-31	2020-05-27	$12.08 million	-$0.14	-$0.16	12.62%
2019-12-31	2020-02-26	$2.21 million	-$0.23	-$0.13	-71.64%
2019-09-30	2019-11-25	$16.87 million	-$0.06	-$0.19	70.27%
2019-06-30	2019-08-29	$1.25 million	-$0.21	-$0.27	24.04%
2019-03-31	2019-05-30	$1.25 million	-$0.25	-$0.26	3.85%
2018-12-31	2019-02-20	$1.87 million	-$0.25	-$0.23	-8.7%
2018-09-30	2018-11-15	$11.64 million	-$0.20	-$0.23	11.52%

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Apr 30 2020	Mar 31 2020
Research Development	N/A	N/A	N/A	N/A	14.38 million
Income Before Tax	N/A	N/A	N/A	N/A	-17.22 million
Selling General Administrative	N/A	N/A	N/A	N/A	5.73 million
Gross Profit	N/A	N/A	N/A	N/A	N/A
Ebit	N/A	N/A	N/A	N/A	-12.54 million
Operating Income	N/A	N/A	N/A	N/A	-15.64 million
Income Tax Expense	74000	-730000	-3.26 million	-3.26 million	-1.96 million
Total Revenue	N/A	N/A	N/A	N/A	12.08 million
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Total Other Income Expense Net	N/A	N/A	N/A	N/A	2.04 million
Net Income From Continuing Operations	N/A	N/A	N/A	N/A	-15.26 million
Net Income Applicable to Common Shares	-25.69 million	-24.54 million	-32.61 million	-32.61 million	-15.26 million

Cash Flow:

Date	Sep 30 2020	Jun 30 2020	Apr 30 2020	Mar 31 2020	Jan 31 2020
Investments	-81000	-1.87 million	-1.87 million	-693000	-693000
Change to Liabilities	N/A	N/A	6.2 million	403000	403000
Total Cash Flow from Investing Activities	N/A	N/A	-1.87 million	-693000	-693000
Net Borrowings	N/A	N/A	-406000	-524000	-524000
Total Cash Flow from Financial Activities	6.54 million	88.92 million	88.92 million	-65000	-65000
Change to Operating Activities	N/A	N/A	2.54 million	-6.51 million	-6.51 million
Change in Cash	N/A	67.47 million	67.47 million	-20.65 million	-20.65 million
Total Cash from Operating Activities	N/A	N/A	-19.58 million	-19.9 million	-19.9 million
Depreciation	N/A	N/A	N/A	946000	946000
Other Cash Flow from Investing Activities	N/A	N/A	N/A	N/A	N/A
Change to Inventory	N/A	N/A	N/A	N/A	N/A
Change to Account Receivables	N/A	N/A	N/A	64000	64000
Other Cash Flow from Financing Activities	N/A	N/A	-4.07 million	-47000	-47000
Change to Net Income	N/A	N/A	1.84 million	463000	463000
Capital Expenditures	81000	841000	841000	693000	693000

Balance Sheet:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Apr 30 2020	Mar 31 2020
Total Liabailities	N/A	N/A	N/A	N/A	177.98 million
Total Stockholder Equity	N/A	N/A	N/A	N/A	487.81 million
Other Current Liabilities	18.31 million	22.22 million	N/A	N/A	N/A
Total Assets	N/A	N/A	N/A	N/A	665.79 million
Common Stock	1.07 billion	1.06 billion	1.05 billion	N/A	960.45 million
Other Current Assets	N/A	N/A	N/A	1.05 billion	N/A
Retained Earnings	-598.99 million	-573.3 million	-548.76 million	-548.76 million	-516.15 million
Other Liabilities	21.94 million	23.22 million	30.79 million	30.79 million	35.58 million
Other Assets	3.21 million	3.33 million	3.31 million	3.31 million	3.24 million
Cash	N/A	N/A	N/A	N/A	60.08 million
Total Current Liabilities	91.04 million	87.7 million	N/A	N/A	76.69 million
Other Stockholder Equity	52.19 million	48.8 million	46.63 million	46.63 million	43.51 million
Property, Plant & Equipment	10.41 million	10.33 million	10.27 million	10.27 million	9.44 million
Total Current Assets	90.46 million	115.74 million	N/A	N/A	69.39 million
Long Term Investments	N/A	N/A	N/A	N/A	1.77 million
Net Tangible Assets	-62.6 million	-42.71 million	-32.28 million	-32.28 million	-94.13 million
Short Term Investments	N/A	N/A	N/A	N/A	N/A
Long Term Debt	N/A	N/A	N/A	N/A	59.95 million
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Payable	28.61 million	27.6 million	N/A	N/A	19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Show entries

Search:

Expiration Date	Strike	Last Price	Type	Open Interest	Implied Volatility	In the Money
2025-04-17	1	0	CALL	0	0	TRUE
2025-04-17	2	0	CALL	0	0	TRUE
2025-04-17	3	0	CALL	0	1029.5	TRUE
2025-04-17	4	7.8	CALL	0	1316.81	TRUE
2025-04-17	5	12.2	CALL	0	721.18	TRUE
2025-04-17	6	11.4	CALL	2	510.48	TRUE
2025-04-17	7	9.1	CALL	0	545.72	TRUE
2025-04-17	8	7.4	CALL	313	234.03	TRUE
2025-04-17	9	1.13	CALL	46	231.66	TRUE
2025-04-17	10	1.12	CALL	361	151.92	TRUE
2025-04-17	11	0.38	CALL	371	236.24	FALSE
2025-04-17	12	0.15	CALL	68	419.78	FALSE
2025-04-17	13	0.02	CALL	254	541.68	FALSE
2025-04-17	14	0.15	CALL	96	264.17	FALSE
2025-04-17	15	0.2	CALL	1449	521	FALSE
2025-04-17	16	0.1	CALL	56	391.83	FALSE
2025-04-17	17	0.15	CALL	117	394.85	FALSE
2025-04-17	18	0.3	CALL	405	336.81	FALSE
2025-04-17	19	0.24	CALL	265	1230.21	FALSE
2025-04-17	20	0.63	CALL	1242	391.97	FALSE

Latest MESO Trades:

Date	Shares	Price
Jun 13, 2022 7:57 PM EST	186	$2.66
Jun 13, 2022 7:57 PM EST	14	$2.66
Jun 13, 2022 7:54 PM EST	100	$2.645
Jun 13, 2022 7:54 PM EST	100	$2.645
Jun 13, 2022 7:55 PM EST	100	$2.64

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Show entries

Search:

Date	Form Type	View
2020-11-03	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-10-29	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-10-23	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-10-15	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-10-05	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-09-17	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-09-16	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-09-08	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-09-03	20-F (Annual and transition report of foreign private issuers [Sections 13 or 15(d)])
2020-09-03	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-31	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-25	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-17	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-12	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-10	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-08-03	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-07-27	S-8 (Securities to be offered to employees in employee benefit plans)
2020-07-27	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-07-10	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])
2020-07-07	6-K (Report of foreign issuer [Rules 13a-16 and 15d-16])

Mesoblast Limited

(NASDAQ:MESO)

$6.74

STRONG BUY

Latest On Mesoblast Limited (MESO):

About Mesoblast Limited (MESO):

General

Valuation

Financials

Highlights

Share Statistics

Technicals

Dividends

Mesoblast Limited (MESO) Dividend Calendar:

Mesoblast Limited (MESO) Earnings History:

Mesoblast Limited (MESO) Company Financial Statements:

Income Statement:

Cash Flow:

Balance Sheet:

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Mesoblast Limited (MESO) Options:

Latest MESO Trades:

Mesoblast Limited (MESO) SEC Filings: